Global Neurological Biomarker Market
Global Neurological Biomarker Market

Neurological Biomarker Comprehensive Study by Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, Genomics Biomarkers), Application (Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Depression, Schizophrenia, Huntingtonís Disease, Parkinsonís Disease, Alzheimerís Disease), End User (Hospitals, Research Institutes, Diagnostic Centers) Players and Region - Global Market Outlook to 2024

Neurological Biomarker Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 9.91%  

Jul 2019 Edition 241 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Neurological Biomarker Market Scope
Neurological biomarkers assist in inspecting and analyzing neurological diseases since it provides a strong approach for understanding the properties of the neurological disease with numerous applications in randomized clinical trials analytic epidemiology, prognosis, and screening & diagnosis. Over the past few decades, unhealthier and unfavorable lifestyles have led to an increasing prevalence of neurological disorders across the global population. Careful assessment of the validity of biomarkers is required with respect to the stage of the disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory.

The market study is being classified by Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers and Genomics Biomarkers), by Application (Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Depression, Schizophrenia, Huntingtonís Disease, Parkinsonís Disease and Alzheimerís Disease) and major geographies with country level break-up. According to AMA, the Global Neurological Biomarker market is expected to see growth rate of 9.91% and may see market size of USD7806.2 Million by 2024.

The Players having a strong hold in the market are Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, and, Athena Diagnostics. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neurological Biomarker market throughout the predicted period.

Abbott Laboratories (United States), Myriad RBM Inc. (United States), Proteome Sciences (United Kingdom), Thermo Fisher Scientific (United States), Athena Diagnostics (India), Immunarray Pvt Ltd (Israel), Quanterix Corporation (United States), Diagenic ASA (Norway), Psynova Neurotech Ltd (United Kingdom) and Bio-Rad Laboratories, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Qiagen (Germany), AbaStar MDx, Inc. (United States), Acumen Pharmaceuticals, Inc. (United States) and Abiant, Inc. (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Neurological Biomarker market by Type, Application and Region. On the basis of Type, Genomics Biomarkers are dominating the market in the year 2018

On the basis of geography, the market of Neurological Biomarker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North Amercia region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Neurological Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On June 17, 2019, the global humanitarian organization CARE, the healthcare company Abbott and its foundation the Abbott Fund has announced a three-year partnership valued at 1 million USD which will assist in screening, diagnosing, preventing and managing and managing of noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Philippines.

The FDAís Center for Devices and Radiological Health (CDRH) conducts research to support science-based and transparent decisions and minimize assumptions and subjectivity in the device review process. FDA scientists advance regulatory science by developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of medical devices.

Market Trend
  • Upsurging Technological Advancements in Molecular Biology and Laboratory Technology
  • Rising Prevalence of Alzheimers and Parkinsons Diseases

Market Drivers
  • Assists in Inspecting and Analysing Neurological Diseases
  • Increasing Neurological Disorders across the Global Population

Opportunities
  • Increasing Preferences Towards Customized and Personalised Medicines Across the Globe
  • Robustly Growing Healthcare Infrastructure from Emerging Economies

Restraints
  • Lack of Awareness about the Neurological Biomarker from Underdeveloped Economies
  • Comparatively Expensive Solutions and Prone to Laboratory Errors might Stagnate the Demand

Challenges
  • A dearth of Skilled Neurologists across the Globe


Key Target Audience
Neurological Biomarker Manufacturers, Neurological Biomarker Distributors and Traders, Neurological Biomarker Upstream and Downstream Buyers, Health Care Industry Associations, Research and Development Organizations, Government Regulators, Financial Institutes and Non-Profit Organizations and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Imaging Biomarkers
  • Metabolomics Biomarkers
  • Proteomic Biomarkers
  • Genomics Biomarkers
By Application
  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Depression
  • Schizophrenia
  • Huntingtonís Disease
  • Parkinsonís Disease
  • Alzheimerís Disease
By End User
  • Hospitals
  • Research Institutes
  • Diagnostic Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Assists in Inspecting and Analysing Neurological Diseases
      • 3.2.2. Increasing Neurological Disorders across the Global Population
    • 3.3. Market Challenges
      • 3.3.1. A dearth of Skilled Neurologists across the Globe
    • 3.4. Market Trends
      • 3.4.1. Upsurging Technological Advancements in Molecular Biology and Laboratory Technology
      • 3.4.2. Rising Prevalence of Alzheimers and Parkinsons Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurological Biomarker, by Type, Application, End User and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Neurological Biomarker (Value)
      • 5.2.1. Global Neurological Biomarker by: Type (Value)
        • 5.2.1.1. Imaging Biomarkers
        • 5.2.1.2. Metabolomics Biomarkers
        • 5.2.1.3. Proteomic Biomarkers
        • 5.2.1.4. Genomics Biomarkers
      • 5.2.2. Global Neurological Biomarker by: Application (Value)
        • 5.2.2.1. Spinal Muscular Atrophy (SMA)
        • 5.2.2.2. Multiple Sclerosis
        • 5.2.2.3. Depression
        • 5.2.2.4. Schizophrenia
        • 5.2.2.5. Huntingtonís Disease
        • 5.2.2.6. Parkinsonís Disease
        • 5.2.2.7. Alzheimerís Disease
      • 5.2.3. Global Neurological Biomarker by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Diagnostic Centers
      • 5.2.4. Global Neurological Biomarker Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Neurological Biomarker (Volume)
      • 5.3.1. Global Neurological Biomarker by: Type (Volume)
        • 5.3.1.1. Imaging Biomarkers
        • 5.3.1.2. Metabolomics Biomarkers
        • 5.3.1.3. Proteomic Biomarkers
        • 5.3.1.4. Genomics Biomarkers
      • 5.3.2. Global Neurological Biomarker by: Application (Volume)
        • 5.3.2.1. Spinal Muscular Atrophy (SMA)
        • 5.3.2.2. Multiple Sclerosis
        • 5.3.2.3. Depression
        • 5.3.2.4. Schizophrenia
        • 5.3.2.5. Huntingtonís Disease
        • 5.3.2.6. Parkinsonís Disease
        • 5.3.2.7. Alzheimerís Disease
      • 5.3.3. Global Neurological Biomarker by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Research Institutes
        • 5.3.3.3. Diagnostic Centers
      • 5.3.4. Global Neurological Biomarker Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Neurological Biomarker (Price)
      • 5.4.1. Global Neurological Biomarker by: Type (Price)
  • 6. Neurological Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Myriad RBM Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Proteome Sciences (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Athena Diagnostics (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Immunarray Pvt Ltd (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quanterix Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Diagenic ASA (Norway)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Psynova Neurotech Ltd (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neurological Biomarker Sale, by Type, Application, End User and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Neurological Biomarker (Value)
      • 7.2.1. Global Neurological Biomarker by: Type (Value)
        • 7.2.1.1. Imaging Biomarkers
        • 7.2.1.2. Metabolomics Biomarkers
        • 7.2.1.3. Proteomic Biomarkers
        • 7.2.1.4. Genomics Biomarkers
      • 7.2.2. Global Neurological Biomarker by: Application (Value)
        • 7.2.2.1. Spinal Muscular Atrophy (SMA)
        • 7.2.2.2. Multiple Sclerosis
        • 7.2.2.3. Depression
        • 7.2.2.4. Schizophrenia
        • 7.2.2.5. Huntingtonís Disease
        • 7.2.2.6. Parkinsonís Disease
        • 7.2.2.7. Alzheimerís Disease
      • 7.2.3. Global Neurological Biomarker by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Diagnostic Centers
      • 7.2.4. Global Neurological Biomarker Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Neurological Biomarker (Volume)
      • 7.3.1. Global Neurological Biomarker by: Type (Volume)
        • 7.3.1.1. Imaging Biomarkers
        • 7.3.1.2. Metabolomics Biomarkers
        • 7.3.1.3. Proteomic Biomarkers
        • 7.3.1.4. Genomics Biomarkers
      • 7.3.2. Global Neurological Biomarker by: Application (Volume)
        • 7.3.2.1. Spinal Muscular Atrophy (SMA)
        • 7.3.2.2. Multiple Sclerosis
        • 7.3.2.3. Depression
        • 7.3.2.4. Schizophrenia
        • 7.3.2.5. Huntingtonís Disease
        • 7.3.2.6. Parkinsonís Disease
        • 7.3.2.7. Alzheimerís Disease
      • 7.3.3. Global Neurological Biomarker by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Research Institutes
        • 7.3.3.3. Diagnostic Centers
      • 7.3.4. Global Neurological Biomarker Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Neurological Biomarker (Price)
      • 7.4.1. Global Neurological Biomarker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurological Biomarker: by Type(USD Million)
  • Table 2. Neurological Biomarker Imaging Biomarkers , by Region USD Million (2013-2018)
  • Table 3. Neurological Biomarker Metabolomics Biomarkers , by Region USD Million (2013-2018)
  • Table 4. Neurological Biomarker Proteomic Biomarkers , by Region USD Million (2013-2018)
  • Table 5. Neurological Biomarker Genomics Biomarkers , by Region USD Million (2013-2018)
  • Table 6. Neurological Biomarker: by Application(USD Million)
  • Table 7. Neurological Biomarker Spinal Muscular Atrophy (SMA) , by Region USD Million (2013-2018)
  • Table 8. Neurological Biomarker Multiple Sclerosis , by Region USD Million (2013-2018)
  • Table 9. Neurological Biomarker Depression , by Region USD Million (2013-2018)
  • Table 10. Neurological Biomarker Schizophrenia , by Region USD Million (2013-2018)
  • Table 11. Neurological Biomarker Huntingtonís Disease , by Region USD Million (2013-2018)
  • Table 12. Neurological Biomarker Parkinsonís Disease , by Region USD Million (2013-2018)
  • Table 13. Neurological Biomarker Alzheimerís Disease , by Region USD Million (2013-2018)
  • Table 14. Neurological Biomarker: by End User(USD Million)
  • Table 15. Neurological Biomarker Hospitals , by Region USD Million (2013-2018)
  • Table 16. Neurological Biomarker Research Institutes , by Region USD Million (2013-2018)
  • Table 17. Neurological Biomarker Diagnostic Centers , by Region USD Million (2013-2018)
  • Table 18. South America Neurological Biomarker, by Country USD Million (2013-2018)
  • Table 19. South America Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 20. South America Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 21. South America Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 22. Brazil Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 23. Brazil Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 24. Brazil Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 25. Argentina Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 26. Argentina Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 27. Argentina Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 28. Rest of South America Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 29. Rest of South America Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 30. Rest of South America Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 31. Asia Pacific Neurological Biomarker, by Country USD Million (2013-2018)
  • Table 32. Asia Pacific Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 33. Asia Pacific Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 34. Asia Pacific Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 35. China Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 36. China Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 37. China Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 38. Japan Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 39. Japan Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 40. Japan Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 41. India Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 42. India Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 43. India Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 44. South Korea Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 45. South Korea Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 46. South Korea Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 47. Taiwan Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 48. Taiwan Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 49. Taiwan Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 50. Australia Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 51. Australia Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 52. Australia Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 54. Rest of Asia-Pacific Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 55. Rest of Asia-Pacific Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 56. Europe Neurological Biomarker, by Country USD Million (2013-2018)
  • Table 57. Europe Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 58. Europe Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 59. Europe Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 60. Germany Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 61. Germany Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 62. Germany Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 63. France Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 64. France Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 65. France Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 66. Italy Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 67. Italy Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 68. Italy Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 69. United Kingdom Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 70. United Kingdom Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 71. United Kingdom Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 72. Netherlands Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 73. Netherlands Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 74. Netherlands Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 75. Rest of Europe Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 76. Rest of Europe Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 77. Rest of Europe Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 78. MEA Neurological Biomarker, by Country USD Million (2013-2018)
  • Table 79. MEA Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 80. MEA Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 81. MEA Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 82. Middle East Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 83. Middle East Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 84. Middle East Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 85. Africa Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 86. Africa Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 87. Africa Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 88. North America Neurological Biomarker, by Country USD Million (2013-2018)
  • Table 89. North America Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 90. North America Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 91. North America Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 92. United States Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 93. United States Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 94. United States Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 95. Canada Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 96. Canada Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 97. Canada Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 98. Mexico Neurological Biomarker, by Type USD Million (2013-2018)
  • Table 99. Mexico Neurological Biomarker, by Application USD Million (2013-2018)
  • Table 100. Mexico Neurological Biomarker, by End User USD Million (2013-2018)
  • Table 101. Neurological Biomarker Sales: by Type(K Units)
  • Table 102. Neurological Biomarker Sales Imaging Biomarkers , by Region K Units (2013-2018)
  • Table 103. Neurological Biomarker Sales Metabolomics Biomarkers , by Region K Units (2013-2018)
  • Table 104. Neurological Biomarker Sales Proteomic Biomarkers , by Region K Units (2013-2018)
  • Table 105. Neurological Biomarker Sales Genomics Biomarkers , by Region K Units (2013-2018)
  • Table 106. Neurological Biomarker Sales: by Application(K Units)
  • Table 107. Neurological Biomarker Sales Spinal Muscular Atrophy (SMA) , by Region K Units (2013-2018)
  • Table 108. Neurological Biomarker Sales Multiple Sclerosis , by Region K Units (2013-2018)
  • Table 109. Neurological Biomarker Sales Depression , by Region K Units (2013-2018)
  • Table 110. Neurological Biomarker Sales Schizophrenia , by Region K Units (2013-2018)
  • Table 111. Neurological Biomarker Sales Huntingtonís Disease , by Region K Units (2013-2018)
  • Table 112. Neurological Biomarker Sales Parkinsonís Disease , by Region K Units (2013-2018)
  • Table 113. Neurological Biomarker Sales Alzheimerís Disease , by Region K Units (2013-2018)
  • Table 114. Neurological Biomarker Sales: by End User(K Units)
  • Table 115. Neurological Biomarker Sales Hospitals , by Region K Units (2013-2018)
  • Table 116. Neurological Biomarker Sales Research Institutes , by Region K Units (2013-2018)
  • Table 117. Neurological Biomarker Sales Diagnostic Centers , by Region K Units (2013-2018)
  • Table 118. South America Neurological Biomarker Sales, by Country K Units (2013-2018)
  • Table 119. South America Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 120. South America Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 121. South America Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 122. Brazil Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 123. Brazil Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 124. Brazil Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 125. Argentina Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 126. Argentina Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 127. Argentina Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 128. Rest of South America Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 129. Rest of South America Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 130. Rest of South America Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 131. Asia Pacific Neurological Biomarker Sales, by Country K Units (2013-2018)
  • Table 132. Asia Pacific Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 133. Asia Pacific Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 134. Asia Pacific Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 135. China Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 136. China Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 137. China Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 138. Japan Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 139. Japan Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 140. Japan Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 141. India Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 142. India Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 143. India Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 144. South Korea Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 145. South Korea Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 146. South Korea Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 147. Taiwan Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 148. Taiwan Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 149. Taiwan Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 150. Australia Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 151. Australia Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 152. Australia Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 153. Rest of Asia-Pacific Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 154. Rest of Asia-Pacific Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 155. Rest of Asia-Pacific Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 156. Europe Neurological Biomarker Sales, by Country K Units (2013-2018)
  • Table 157. Europe Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 158. Europe Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 159. Europe Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 160. Germany Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 161. Germany Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 162. Germany Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 163. France Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 164. France Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 165. France Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 166. Italy Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 167. Italy Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 168. Italy Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 169. United Kingdom Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 170. United Kingdom Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 171. United Kingdom Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 172. Netherlands Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 173. Netherlands Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 174. Netherlands Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 175. Rest of Europe Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 176. Rest of Europe Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 177. Rest of Europe Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 178. MEA Neurological Biomarker Sales, by Country K Units (2013-2018)
  • Table 179. MEA Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 180. MEA Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 181. MEA Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 182. Middle East Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 183. Middle East Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 184. Middle East Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 185. Africa Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 186. Africa Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 187. Africa Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 188. North America Neurological Biomarker Sales, by Country K Units (2013-2018)
  • Table 189. North America Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 190. North America Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 191. North America Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 192. United States Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 193. United States Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 194. United States Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 195. Canada Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 196. Canada Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 197. Canada Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 198. Mexico Neurological Biomarker Sales, by Type K Units (2013-2018)
  • Table 199. Mexico Neurological Biomarker Sales, by Application K Units (2013-2018)
  • Table 200. Mexico Neurological Biomarker Sales, by End User K Units (2013-2018)
  • Table 201. Neurological Biomarker: by Type(USD/Units)
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Neurological Biomarker: by Type(USD Million)
  • Table 213. Neurological Biomarker Imaging Biomarkers , by Region USD Million (2019-2024)
  • Table 214. Neurological Biomarker Metabolomics Biomarkers , by Region USD Million (2019-2024)
  • Table 215. Neurological Biomarker Proteomic Biomarkers , by Region USD Million (2019-2024)
  • Table 216. Neurological Biomarker Genomics Biomarkers , by Region USD Million (2019-2024)
  • Table 217. Neurological Biomarker: by Application(USD Million)
  • Table 218. Neurological Biomarker Spinal Muscular Atrophy (SMA) , by Region USD Million (2019-2024)
  • Table 219. Neurological Biomarker Multiple Sclerosis , by Region USD Million (2019-2024)
  • Table 220. Neurological Biomarker Depression , by Region USD Million (2019-2024)
  • Table 221. Neurological Biomarker Schizophrenia , by Region USD Million (2019-2024)
  • Table 222. Neurological Biomarker Huntingtonís Disease , by Region USD Million (2019-2024)
  • Table 223. Neurological Biomarker Parkinsonís Disease , by Region USD Million (2019-2024)
  • Table 224. Neurological Biomarker Alzheimerís Disease , by Region USD Million (2019-2024)
  • Table 225. Neurological Biomarker: by End User(USD Million)
  • Table 226. Neurological Biomarker Hospitals , by Region USD Million (2019-2024)
  • Table 227. Neurological Biomarker Research Institutes , by Region USD Million (2019-2024)
  • Table 228. Neurological Biomarker Diagnostic Centers , by Region USD Million (2019-2024)
  • Table 229. South America Neurological Biomarker, by Country USD Million (2019-2024)
  • Table 230. South America Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 231. South America Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 232. South America Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 233. Brazil Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 234. Brazil Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 235. Brazil Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 236. Argentina Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 237. Argentina Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 238. Argentina Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 239. Rest of South America Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 240. Rest of South America Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 241. Rest of South America Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 242. Asia Pacific Neurological Biomarker, by Country USD Million (2019-2024)
  • Table 243. Asia Pacific Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 244. Asia Pacific Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 245. Asia Pacific Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 246. China Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 247. China Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 248. China Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 249. Japan Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 250. Japan Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 251. Japan Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 252. India Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 253. India Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 254. India Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 255. South Korea Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 256. South Korea Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 257. South Korea Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 258. Taiwan Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 259. Taiwan Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 260. Taiwan Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 261. Australia Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 262. Australia Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 263. Australia Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 264. Rest of Asia-Pacific Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 265. Rest of Asia-Pacific Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 266. Rest of Asia-Pacific Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 267. Europe Neurological Biomarker, by Country USD Million (2019-2024)
  • Table 268. Europe Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 269. Europe Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 270. Europe Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 271. Germany Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 272. Germany Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 273. Germany Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 274. France Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 275. France Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 276. France Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 277. Italy Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 278. Italy Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 279. Italy Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 280. United Kingdom Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 281. United Kingdom Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 282. United Kingdom Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 283. Netherlands Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 284. Netherlands Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 285. Netherlands Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 286. Rest of Europe Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 287. Rest of Europe Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 288. Rest of Europe Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 289. MEA Neurological Biomarker, by Country USD Million (2019-2024)
  • Table 290. MEA Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 291. MEA Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 292. MEA Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 293. Middle East Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 294. Middle East Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 295. Middle East Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 296. Africa Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 297. Africa Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 298. Africa Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 299. North America Neurological Biomarker, by Country USD Million (2019-2024)
  • Table 300. North America Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 301. North America Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 302. North America Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 303. United States Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 304. United States Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 305. United States Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 306. Canada Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 307. Canada Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 308. Canada Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 309. Mexico Neurological Biomarker, by Type USD Million (2019-2024)
  • Table 310. Mexico Neurological Biomarker, by Application USD Million (2019-2024)
  • Table 311. Mexico Neurological Biomarker, by End User USD Million (2019-2024)
  • Table 312. Neurological Biomarker Sales: by Type(K Units)
  • Table 313. Neurological Biomarker Sales Imaging Biomarkers , by Region K Units (2019-2024)
  • Table 314. Neurological Biomarker Sales Metabolomics Biomarkers , by Region K Units (2019-2024)
  • Table 315. Neurological Biomarker Sales Proteomic Biomarkers , by Region K Units (2019-2024)
  • Table 316. Neurological Biomarker Sales Genomics Biomarkers , by Region K Units (2019-2024)
  • Table 317. Neurological Biomarker Sales: by Application(K Units)
  • Table 318. Neurological Biomarker Sales Spinal Muscular Atrophy (SMA) , by Region K Units (2019-2024)
  • Table 319. Neurological Biomarker Sales Multiple Sclerosis , by Region K Units (2019-2024)
  • Table 320. Neurological Biomarker Sales Depression , by Region K Units (2019-2024)
  • Table 321. Neurological Biomarker Sales Schizophrenia , by Region K Units (2019-2024)
  • Table 322. Neurological Biomarker Sales Huntingtonís Disease , by Region K Units (2019-2024)
  • Table 323. Neurological Biomarker Sales Parkinsonís Disease , by Region K Units (2019-2024)
  • Table 324. Neurological Biomarker Sales Alzheimerís Disease , by Region K Units (2019-2024)
  • Table 325. Neurological Biomarker Sales: by End User(K Units)
  • Table 326. Neurological Biomarker Sales Hospitals , by Region K Units (2019-2024)
  • Table 327. Neurological Biomarker Sales Research Institutes , by Region K Units (2019-2024)
  • Table 328. Neurological Biomarker Sales Diagnostic Centers , by Region K Units (2019-2024)
  • Table 329. South America Neurological Biomarker Sales, by Country K Units (2019-2024)
  • Table 330. South America Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 331. South America Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 332. South America Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 333. Brazil Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 334. Brazil Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 335. Brazil Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 336. Argentina Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 337. Argentina Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 338. Argentina Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 339. Rest of South America Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 340. Rest of South America Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 341. Rest of South America Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 342. Asia Pacific Neurological Biomarker Sales, by Country K Units (2019-2024)
  • Table 343. Asia Pacific Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 344. Asia Pacific Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 345. Asia Pacific Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 346. China Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 347. China Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 348. China Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 349. Japan Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 350. Japan Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 351. Japan Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 352. India Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 353. India Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 354. India Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 355. South Korea Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 356. South Korea Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 357. South Korea Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 358. Taiwan Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 359. Taiwan Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 360. Taiwan Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 361. Australia Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 362. Australia Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 363. Australia Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 364. Rest of Asia-Pacific Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 365. Rest of Asia-Pacific Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 366. Rest of Asia-Pacific Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 367. Europe Neurological Biomarker Sales, by Country K Units (2019-2024)
  • Table 368. Europe Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 369. Europe Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 370. Europe Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 371. Germany Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 372. Germany Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 373. Germany Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 374. France Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 375. France Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 376. France Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 377. Italy Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 378. Italy Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 379. Italy Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 380. United Kingdom Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 381. United Kingdom Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 382. United Kingdom Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 383. Netherlands Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 384. Netherlands Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 385. Netherlands Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 386. Rest of Europe Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 387. Rest of Europe Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 388. Rest of Europe Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 389. MEA Neurological Biomarker Sales, by Country K Units (2019-2024)
  • Table 390. MEA Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 391. MEA Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 392. MEA Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 393. Middle East Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 394. Middle East Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 395. Middle East Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 396. Africa Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 397. Africa Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 398. Africa Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 399. North America Neurological Biomarker Sales, by Country K Units (2019-2024)
  • Table 400. North America Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 401. North America Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 402. North America Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 403. United States Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 404. United States Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 405. United States Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 406. Canada Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 407. Canada Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 408. Canada Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 409. Mexico Neurological Biomarker Sales, by Type K Units (2019-2024)
  • Table 410. Mexico Neurological Biomarker Sales, by Application K Units (2019-2024)
  • Table 411. Mexico Neurological Biomarker Sales, by End User K Units (2019-2024)
  • Table 412. Neurological Biomarker: by Type(USD/Units)
  • Table 413. Research Programs/Design for This Report
  • Table 414. Key Data Information from Secondary Sources
  • Table 415. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurological Biomarker: by Type USD Million (2013-2018)
  • Figure 5. Global Neurological Biomarker: by Application USD Million (2013-2018)
  • Figure 6. Global Neurological Biomarker: by End User USD Million (2013-2018)
  • Figure 7. South America Neurological Biomarker Share (%), by Country
  • Figure 8. Asia Pacific Neurological Biomarker Share (%), by Country
  • Figure 9. Europe Neurological Biomarker Share (%), by Country
  • Figure 10. MEA Neurological Biomarker Share (%), by Country
  • Figure 11. North America Neurological Biomarker Share (%), by Country
  • Figure 12. Global Neurological Biomarker: by Type K Units (2013-2018)
  • Figure 13. Global Neurological Biomarker: by Application K Units (2013-2018)
  • Figure 14. Global Neurological Biomarker: by End User K Units (2013-2018)
  • Figure 15. South America Neurological Biomarker Share (%), by Country
  • Figure 16. Asia Pacific Neurological Biomarker Share (%), by Country
  • Figure 17. Europe Neurological Biomarker Share (%), by Country
  • Figure 18. MEA Neurological Biomarker Share (%), by Country
  • Figure 19. North America Neurological Biomarker Share (%), by Country
  • Figure 20. Global Neurological Biomarker: by Type USD/Units (2013-2018)
  • Figure 21. Global Neurological Biomarker share by Players 2018 (%)
  • Figure 22. Global Neurological Biomarker share by Players (Top 3) 2018(%)
  • Figure 23. Global Neurological Biomarker share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 27. Myriad RBM Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Myriad RBM Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Proteome Sciences (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Proteome Sciences (United Kingdom) Revenue: by Geography 2018
  • Figure 31. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 33. Athena Diagnostics (India) Revenue, Net Income and Gross profit
  • Figure 34. Athena Diagnostics (India) Revenue: by Geography 2018
  • Figure 35. Immunarray Pvt Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Immunarray Pvt Ltd (Israel) Revenue: by Geography 2018
  • Figure 37. Quanterix Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Quanterix Corporation (United States) Revenue: by Geography 2018
  • Figure 39. Diagenic ASA (Norway) Revenue, Net Income and Gross profit
  • Figure 40. Diagenic ASA (Norway) Revenue: by Geography 2018
  • Figure 41. Psynova Neurotech Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. Psynova Neurotech Ltd (United Kingdom) Revenue: by Geography 2018
  • Figure 43. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Global Neurological Biomarker: by Type USD Million (2019-2024)
  • Figure 46. Global Neurological Biomarker: by Application USD Million (2019-2024)
  • Figure 47. Global Neurological Biomarker: by End User USD Million (2019-2024)
  • Figure 48. South America Neurological Biomarker Share (%), by Country
  • Figure 49. Asia Pacific Neurological Biomarker Share (%), by Country
  • Figure 50. Europe Neurological Biomarker Share (%), by Country
  • Figure 51. MEA Neurological Biomarker Share (%), by Country
  • Figure 52. North America Neurological Biomarker Share (%), by Country
  • Figure 53. Global Neurological Biomarker: by Type K Units (2019-2024)
  • Figure 54. Global Neurological Biomarker: by Application K Units (2019-2024)
  • Figure 55. Global Neurological Biomarker: by End User K Units (2019-2024)
  • Figure 56. South America Neurological Biomarker Share (%), by Country
  • Figure 57. Asia Pacific Neurological Biomarker Share (%), by Country
  • Figure 58. Europe Neurological Biomarker Share (%), by Country
  • Figure 59. MEA Neurological Biomarker Share (%), by Country
  • Figure 60. North America Neurological Biomarker Share (%), by Country
  • Figure 61. Global Neurological Biomarker: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Myriad RBM Inc. (United States)
  • Proteome Sciences (United Kingdom)
  • Thermo Fisher Scientific (United States)
  • Athena Diagnostics (India)
  • Immunarray Pvt Ltd (Israel)
  • Quanterix Corporation (United States)
  • Diagenic ASA (Norway)
  • Psynova Neurotech Ltd (United Kingdom)
  • Bio-Rad Laboratories, Inc. (United States)
Additional players considered in the study are as follows:
Qiagen (Germany) , AbaStar MDx, Inc. (United States) , Acumen Pharmaceuticals, Inc. (United States) , Abiant, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation